For a while, it seemed the streak was over for Eli Lilly (NYSE: LLY). Shares of the big drugmaker skyrocketed nearly 160% between early 2023 and mid-July of this year. However, Lilly's stock plunged almost 19% afterward -- until last week.
On Aug. 8, Lilly reported stellar second-quarter results and the pharma stock quickly soared more than 15%. Here's why Lilly's big jump last week could be just the beginning of another huge run.
Mounjaro and Zepbound are gaining in popularity
Recent optimism around the stock is largely due to robust sales for three products: Mounjaro, Zepbound, and Verzenio. While sales for blockbuster breast cancer drug Verzenio vaulted 44% higher in the reported quarter, investors were even more excited about the results for Mounjaro and Zepbound, used to treat diabetes and promote weight loss.
Mounjaro's sales more than tripled year over year in Q2 to nearly $3.1 billion. Sales for Zepbound, which won U.S. Food and Drug Administration (FDA) approval in November 2023, topped $1.2 billion in the second quarter.
Under the hood, Mounjaro and Zepbound are the same drug -- tirzepatide. Lilly markets Mounjaro in the U.S. as a treatment for type 2 diabetes (T2D) and outside the U.S. for both T2D and obesity. In the U.S., the company uses the Zepbound brand for the obesity indication.
Lilly raised its full-year 2024 revenue guidance by $3 billion, to between $45.4 billion and $46.6 billion. The company unsurprisingly attributed this improved outlook primarily to "the strong performance of Mounjaro and Zepbound."
But Mounjaro and Zepbound are only warming up. Analysts surveyed by FactSet project the two products will generate combined sales of over $50 billion by 2029.
More on the way
The company has more potential rising stars in its lineup and pipeline.
The FDA approved Kisunla last month as a treatment for early stage Alzheimer's disease. Analysts expect the drug to generate peak annual sales in the ballpark of $5 billion.
Lilly also has great expectations for tirzepatide in treating indications other than T2D and obesity. It recently filed for regulatory approvals in the U.S. and EU of the drug in treating obstructive sleep apnea in adults with obesity. The company reported positive results earlier this month for the drug in treating patients with heart failure with preserved ejection fraction and obesity. Lilly is also evaluating tirzepatide in a phase 2 clinical study targeting metabolic-associated steatohepatitis (MASH).
And Mounjaro and Zepbound might not be Lilly's only T2D and obesity drugs in the future. The drugmaker has two promising late-stage candidates that target both indications: orforglipron and retatrutide.
Lilly's main drawback
Sales for Mounjaro and Zepbound will almost certainly continue to climb dramatically. Lilly could have key catalysts from FDA approvals and late-stage clinical results of its pipeline programs. Its stock could very well begin another huge run.
There are a few things that could get in the way, though. Competitors could gain market share at Lilly's expense, and it's possible that the company's experimental drugs could flop in clinical studies.
However, arguably the main drawback for Lilly is its valuation. The company now stands as the world's largest drugmaker, with its market cap topping $840 billion, and its forward price-to-earnings ratio around 65. Massive growth expectations are priced into Lilly's shares. Any hiccup along the way could prevent the stock from rising. But the chances that Lilly is at the beginning of another major uptrend still look pretty good.
Should you invest $1,000 in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $668,029!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of August 12, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
